Title:Exploring the Potential of Neuroproteomics in Alzheimer's Disease
Volume: 20
Issue: 25
Author(s): Md. Sahab Uddin*, Md. Tanvir Kabir, Md. Jakaria, Eduardo Sobarzo-Sánchez, George E. Barreto, Asma Perveen, Abdul Hafeez, May N. Bin-Jumah, Mohamed M. Abdel-Daim and Ghulam M. Ashraf*
Affiliation:
- Department of Pharmacy, Southeast University, Dhaka,Bangladesh
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah,Saudi Arabia
Keywords:
Neuroproteomics, Alzheimer's Disease, Amyloid precursor protein, Amyloid-beta, Tau, Microglia, Biomarkers.
Abstract: Alzheimer's disease (AD) is progressive brain amyloidosis that damages brain regions associated
with memory, thinking, behavioral and social skills. Neuropathologically, AD is characterized by
intraneuronal hyperphosphorylated tau inclusions as neurofibrillary tangles (NFTs), and buildup of extracellular
amyloid-beta (Aβ) peptide as senile plaques. Several biomarker tests capturing these pathologies
have been developed. However, for the full clinical expression of the neurodegenerative events of
AD, there exist other central molecular pathways. In terms of understanding the unidentified underlying
processes for the progression and development of AD, a complete comprehension of the structure and
composition of atypical aggregation of proteins is essential. Presently, to aid the prognosis, diagnosis,
detection, and development of drug targets in AD, neuroproteomics is elected as one of the leading essential
tools for the efficient exploratory discovery of prospective biomarker candidates estimated to
play a crucial role. Therefore, the aim of this review is to present the role of neuroproteomics to analyze
the complexity of AD.